Home Featured Page 164

Featured

Latest

President Trump Signs Executive Order to Accelerate Psychedelic Research and Access

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines are reduced to standard protocols

A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and Ketamine Therapy

Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass Launches Provider Training Grants; Therapeutic Alliance Debate Reignites

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange...

PT347 – Christopher Koddermann – Rescheduling Psilocybin, Patents and IP, and...

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business...

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction...

atai Life Sciences Secures Term Loan Facility for up to $175...

Field Trip Announces Closing of Plan of Arrangement and $19.9 Million...

PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support...

Psychedelic Bulletin #114 – Lawsuit Alleges Compass Stole Trade Secrets; MindMed...

EDITOR PICKS

President Trump Signs Executive Order to Accelerate Psychedelic Research and Access

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines...

A Practitioner Statement on the Responsible Development of Ibogaine in the...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

President Trump Signs Executive Order to Accelerate Psychedelic Research and Access

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines are reduced to standard protocols

A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and Ketamine Therapy

Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass Launches Provider Training Grants; Therapeutic Alliance Debate Reignites

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange...

PT347 – Christopher Koddermann – Rescheduling Psilocybin, Patents and IP, and...

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business...

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction...

atai Life Sciences Secures Term Loan Facility for up to $175...

Field Trip Announces Closing of Plan of Arrangement and $19.9 Million...

PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support...

Psychedelic Bulletin #114 – Lawsuit Alleges Compass Stole Trade Secrets; MindMed...

EDITOR PICKS

President Trump Signs Executive Order to Accelerate Psychedelic Research and Access

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines...

A Practitioner Statement on the Responsible Development of Ibogaine in the...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY